132
Participants
Start Date
October 31, 2011
Primary Completion Date
September 30, 2013
Study Completion Date
February 28, 2014
Atazanavir
Capsules, Oral, 300mg, Once daily, 48 weeks
Ritonavir (heat-stable)
Tablets, Oral, 100 mg, Once daily, 48 weeks
Raltegravir
Tablets, Oral, 400 mg, Twice daily, 48 weeks
Tenofovir/Emtricitabine
Tablets, Oral, 300/200 mg, Once daily, 48 weeks
Aids Care, Rochester
Local Institution, Genova
Local Institution, Genova
Local Institution, Milan
Local Institution, Milan
Local Institution, Hamburg
Local Institution, Madrid
Local Institution, Madrid
Local Institution, Madrid
Local Institution, Madrid
Consultive Medicine, Daytona Beach
Orange County Health Dept., Orlando
Triple O Medical Services, P.A., West Palm Beach
Local Institution, Bochum
Local Institution, Orléans
Local Institution, Frankfurt am Main
Local Institution, Frankfurt
Local Institution, Strasbourg
Local Institution, Lyon
Health For Life Clinic Pllc, Little Rock
Local Institution, Paris
Local Institution, Paris
Local Institution, Paris
Local Institution, Munich
Eisenhower Medical Center, Palm Springs
Metropolis Medical Pc, San Francisco
The Research Institute, Springfield
Local Institution, Roma
Local Institution, Warsaw
Local Institution, Wroclaw
Local Institution, Alicante
Local Institution, Barcelona
Local Institution, London
Local Institution, Manchester
Local Institution, Brighton
Local Institution, London
Local Institution, London
Local Institution, Sheffield
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY